Syros to Participate in Upcoming Investor Conferences
Syros to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Details are as follows:
馬薩諸塞州劍橋--（美國商業資訊）-- 錫羅斯製藥 （納斯達克股票代碼：SYRS）是一家致力於推進血液系統惡性腫瘤一線治療新護理標準的生物製藥公司，今天宣佈，公司管理層將參加即將舉行的兩次投資者會議的爐邊談話。詳情如下：
JMP Securities 2024 Life Sciences Conference
Date: Tuesday, May 14
Presentation Time: 11:00 a.m. ET
Location: New York Hilton Midtown, 1335 Sixth Avenue, New York, NY
JMP 證券2024年生命科學會議
日期：5月14日星期二
演講時間：美國東部時間上午 11:00
地點：紐約州紐約市第六大道 1335 號中城希爾頓酒店
TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Date: Wednesday, May 29
Presentation Time: 1:00 p.m. ET
Location: Virtual
TD Cowen的第五屆年度腫瘤學創新峯會：ASCO和EHA的見解
日期：5月29日星期三
演講時間：美國東部時間下午 1:00
地點：虛擬
To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.
要訪問每個活動的網絡直播和隨後的存檔記錄，請訪問Syros網站的 “投資者與媒體” 部分，網址爲 www.syros.com。每個網絡直播的存檔重播將在每次演講結束後的大約30天內提供。
About Syros Pharmaceuticals
關於錫羅斯製藥
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
Syros致力於爲血液惡性腫瘤患者的一線治療制定新的護理標準。出於幫助基本上無法獲得其他靶向治療的血液疾病患者的動機，Syros正在開發tamibarotene，這是一種口服選擇性 RARα激動劑，用於患有高危骨髓增生異常綜合徵和急性髓系白血病的一線患者 RARA 基因過度表達。欲了解更多信息，請訪問 www.syros.com 然後在推特上關注我們 (@SyrosPharma) 和 領英。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507063235/en/
在 businesswire.com 上查看源版本： https://www.businesswire.com/news/home/20240507063235/en/
Syros Contact
Karen Hunady
Director of Corporate Communications & Investor Relations
1-857-327-7321
khunady@syros.com
Syros 聯繫人
凱倫漢迪
企業傳播與投資者關係總監
1-857-327-7321
khunady@syros.com
Investor Contact
Amanda Isacoff
Stern Investor Relations, Inc.
212-362-1200
amanda.isacoff@sternir.com
投資者聯繫人
阿曼達·艾薩科夫
斯特恩投資者關係有限公司
212-362-1200
amanda.isacoff@sternir.com
Source: Syros Pharmaceuticals
來源：錫羅斯製藥
Released May 7, 2024
2024 年 5 月 7 日發佈
譯文內容由第三人軟體翻譯。